Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Our current portfolio includes three late-stage product candidates, Cimzia (certolizumab pegol), for the treatment of moderate to severe plaque psoriasis, DRM04, for the treatment of hyperhidrosis, or excessive sweating and DRM01, a topical sebum inhibitor for acne.
Type
Public
HQ
Menlo Park, US
Founded
2011
Employees
62 (est)+83%
Dermira was founded in 2011 and is headquartered in Menlo Park, US

Key People at Dermira

Thomas G. Wiggans

Thomas G. Wiggans

Co-Founder & CEO
Janice Drew

Janice Drew

Vice President & Project Management
Kin Chan

Kin Chan

Vice President of Engineering
Eugene A. Bauer

Eugene A. Bauer

Founder & Chief Medical Officer
Hans Hofland

Hans Hofland

Vice President ofResearch
Chris Griffith

Chris Griffith

Founder & Vice President, Corporate Development & Strategy

Dermira Locations

Menlo Park, US

Dermira Metrics

Dermira Summary

Market capitalization

$1.11 B

Closing share price

$31
Dermira's latest market capitalization is $1.11 B.

Dermira Market Value History

31% of current employees of Dermira are female and 69% are male.

Dermira Company Life

You may also be interested in